Less than a month after laying off half its staff and leaping onto a life raft thrown by Redx Pharma Plc, Jounce Therapeutics, Inc. has received a takeover offer from another suitor, little-known Concentra Biosciences.
Things have moved fast since the end of February when Jounce announced a 57% reduction of its workforce after saying that advancement of its lead clinical programs, vopratelimab and JTX-8064, "requires funding and a scope that the company cannot pursue on its own." Last summer, the company presented results of the Phase II SELECT trial, saying that the study did not show the requisite difference in tumor shrinkage for vopratelimab, an ICOS agonist, combined with its PD-1 inhibitor, pimivalimab, compared with pimivalimab alone
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?